Drug Type Small molecule drug |
Synonyms FCN 437, FCN-437, FCN-437C |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC29H40N8OS |
InChIKeyPGGPKYATZSPYKB-UHFFFAOYSA-N |
CAS Registry2146171-49-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | NDA/BLA | CN | 21 Nov 2023 | |
Breast Cancer | Phase 3 | CN | 30 Jan 2023 | |
Advanced breast cancer | Phase 3 | CN | 18 Jan 2022 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | CN | 18 Jan 2022 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | CN | 21 Aug 2020 | |
Liver Injury | Phase 1 | CN | 04 Sep 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 25 Jun 2019 |
NCT04488107 (ASCO2022) Manual | Phase 1 | 29 | xxzvxoyqjd(tzfwkyobuw) = oivyzcdoqk rsymimttrq (cvjarxiqik ) View more | Positive | 02 Jun 2022 | ||
jhavmvmolr(gtihxkttmi) = wmvvavlapt qdojeghclx (dlnznawlhz, 47.82 - 100) View more | |||||||
Phase 1 | 17 | eoplcecpfl(lbanohavwx) = cggoiokmlh qtalbqlven (geuefwnxto ) View more | - | 01 Jul 2021 | |||
Phase 1 | - | (tusboyuwri) = avmouxjamw aertxzzatf (wpdvybqdty ) View more | - | 09 Jun 2021 | |||
FCN-437c 100 mg | (tusboyuwri) = pwrtefftco aertxzzatf (wpdvybqdty ) View more |